Indeterminate Dendritic Cell Histiocytosis Harboring <i>ETV3::NCOA2</i> Translocation with Complete Metabolic Response to MEK Inhibition
Indeterminate dendritic cell histiocytosis (IDCH) is a rare condition that usually has cutaneous involvement. Recent studies have revealed that ETV3::NCOA2 translocations are unique to IDCH; however, there are currently no standard treatment options for these rare cases. We present the first reported case of ETV3::NCOA2 positive IDCH that showed complete metabolic response after the initiation of the oral MEK-inhibitor cobimetinib.
Authors
- Lauren Kole (ORCID: https://orcid.org/0000-0001-5552-8193)
- Pradeep Bhambhvani
- Aditi Saha (ORCID: https://orcid.org/0000-0003-3421-3971)
- Lucy Bailey (ORCID: https://orcid.org/0009-0009-4248-5265)
- Vyshnavi Rallapalle (ORCID: https://orcid.org/0000-0002-7388-0390)
- Gaurav Goyal (ORCID: https://orcid.org/0000-0001-6148-5177)
- Shuko Harada (ORCID: https://orcid.org/0000-0002-5783-2049)
- Lauren V. Graham (ORCID: https://orcid.org/0009-0000-4009-3297)
- Dariusz Sokołowski (ORCID: https://orcid.org/0000-0002-8161-6952)
- Aishwarya Ravindran (ORCID: https://orcid.org/0000-0003-4503-440X)
- Jennifer Toral-Orduno
- Brinda H Shukla
Institutions
- University of Alabama at Birmingham (US)
- Birmingham VA Medical Center (US)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-11-14
- DOI
- https://doi.org/10.1093/bjd/ljaf459
- Primary Topic
- Histiocytic Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00